Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
110.00    0.00 (0.00%)
Bid:
107.00
Ask:
113.00
Spread: 6.00 (5.607%)
Market Cap: £14.83m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Director/PDMR Shareholding

5 May 2015 07:01

RNS Number : 0960M
Revolymer PLC
05 May 2015
 

5 May 2015

 

Revolymer plc ("Revolymer" or "the Group")

Awards under Long Term Incentive Plan and other share awards

 

Revolymer (AIM: REVO) announces the grant of awards under the Revolymer plc Long Term Incentive Plan ("LTIP") and other share awards to its executive directors Kevin Matthews and Robin Cridland.

 

The LTIP was adopted by the board of directors of Revolymer plc (the "Board") on 29 June 2012 and its remuneration committee has approved the following grants on 30 April 2015:

· To the CEO Kevin Matthews a nil cost option over 567,568 ordinary shares

· To the CFO Robin Cridland a nil cost option over 349,550 ordinary shares.

 

The vesting period of these grants is three years and they only become exercisable if challenging performance conditions are met; namely that 50% of the grant becomes exercisable if the weighted average ordinary share price in the 180 day period ending on the third anniversary of grant is £0.75. Between weighted average ordinary share prices of £0.75 and £1.00, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below £0.75 the grants are not exercisable and lapse in full.

 

The Board also requires the executive directors to maintain minimum interests (of at least 420,000 ordinary shares for Kevin Matthews and 388,000 ordinary shares for Robin Cridland) before selling any ordinary shares that are the result of exercise, except that they may sell that number of ordinary shares that are required to satisfy any income tax and employee's national insurance liabilities arising at exercise. This requirement shall not apply on a change of control, or other transaction with substantially the same effect.

 

Also on 30 April 2015, the Board authorised the issue to Robin Cridland of 36,036 fully paid up ordinary shares in Revolymer plc ("New Shares") in recognition of his fulfilment of the role of Acting CEO during 2014 before the arrival of Kevin Matthews. Following the issue of the New Shares, Mr Cridland will hold 52,836 ordinary shares representing approximately 0.1% per cent. of the Company's issued share capital.

 

Application has been made to the London Stock Exchange for the 36,036 New Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8:00 am on 8 May 2015. Following Admission, the total number of ordinary shares in the Company will be 56,597,176 with each Ordinary Share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in ACR under the FSA's Disclosure and Transparency Rules.

 

Ends

 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

 

 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Hugh Morgan / Adam James (Corporate Finance)

Charles Leigh-Pemberton (Corporate Broking)

 

 

About Revolymer

Revolymer is an AIM quoted company (registered number 08024489) that designs, develops and formulates novel polymers to improve the performance of its customers' and partners' products.

The vision for Revolymer is to build a high growth, high quality margin, specialty materials business based on proprietary polymer technology that provides responsive or smart multi-functional materials. The Board believes that the Company's technology has broad application. Revolymer aims to generate growing high quality revenue streams by either licensing its proprietary technologies or through the supply of proprietary products using an outsourced manufacturing model. Current target markets are Household Products, Personal Care and Nicotine Gum.

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEANSFEEXSEFF
Date   Source Headline
9th Apr 20211:07 pmRNSIssue of Shares, Director/PDMR Dealings
30th Mar 20217:00 amRNSFull Year Results Ended 31 December 2020
24th Mar 202111:06 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20217:00 amRNSNotice of Final Results and Investor Presentation
23rd Mar 20212:06 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:00 pmRNSPrice Monitoring Extension
23rd Mar 202111:05 amRNSSecond Price Monitoring Extn
23rd Mar 202111:00 amRNSPrice Monitoring Extension
28th Jan 20212:06 pmRNSSecond Price Monitoring Extn
28th Jan 20212:01 pmRNSPrice Monitoring Extension
27th Jan 202111:06 amRNSSecond Price Monitoring Extn
27th Jan 202111:00 amRNSPrice Monitoring Extension
26th Jan 202111:05 amRNSSecond Price Monitoring Extn
26th Jan 202111:00 amRNSPrice Monitoring Extension
26th Jan 20217:00 amRNSTrading Update for the year ended 31 December 2020
21st Jan 202111:05 amRNSSecond Price Monitoring Extn
21st Jan 202111:01 amRNSPrice Monitoring Extension
18th Jan 20212:06 pmRNSSecond Price Monitoring Extn
18th Jan 20212:01 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20212:06 pmRNSSecond Price Monitoring Extn
14th Jan 20212:01 pmRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSAppointment of new Vice President, Operations
8th Jan 202111:06 amRNSSecond Price Monitoring Extn
8th Jan 202111:00 amRNSPrice Monitoring Extension
30th Dec 202011:05 amRNSSecond Price Monitoring Extn
30th Dec 202011:00 amRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20207:00 amRNSAppointment of New Marketing and Sales Executive
28th Oct 20207:00 amRNSHalf Year Results
23rd Oct 20202:30 pmRNSResult of AGM
21st Oct 20207:00 amRNSNotice of Interim Results
13th Oct 202011:06 amRNSSecond Price Monitoring Extn
13th Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20204:35 pmRNSPrice Monitoring Extension
2nd Oct 20203:17 pmRNSCorrection to Full Year Results
30th Sep 20207:00 amRNSFull Year Results
16th Sep 20208:00 amRNSHolding(s) in Company
15th Sep 20207:00 amRNSNotice of Results
22nd Jul 20207:14 amRNSH1 2020 Trading Update
17th Jul 20201:36 pmRNSHolding(s) in Company
17th Jul 202011:18 amRNSHolding(s) in Company
15th Jul 20203:04 pmRNSDirector/PDMR Shareholding
14th Jul 202012:51 pmRNSResult of General Meeting
26th Jun 20206:01 pmRNSNotice of GM and Posting of Circular
24th Jun 20203:33 pmRNSResult of Fundraise
24th Jun 20207:55 amRNSClose of Accelerated Bookbuild

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.